FYmika-250
Description_Effects
Fymika-250 is an antibiotic used for the treatment of serious bacterial infections affecting various parts of the body. It contains Amikacin 250 mg, which belongs to the aminoglycoside class of antibiotics. This medication works by inhibiting bacterial protein synthesis, thereby stopping the growth and multiplication of bacteria. It is effective against a broad spectrum of Gram-negative and some Gram-positive bacteria, including strains resistant to other antibiotics. Fymika-250 is typically administered via intramuscular or intravenous injection in hospital or clinical settings. It is commonly used in the management of severe infections such as bacterial meningitis, respiratory tract infections, urinary tract infections (UTIs), bone and joint infections, abdominal infections, blood infections (septicemia), and infections of the skin and soft tissues. Because of its potential side effects, especially those related to kidney function and hearing, patients on Fymika-250 are usually monitored closely through blood tests and hearing assessments. The risk of toxicity increases with prolonged use, high doses, or in patients with pre-existing kidney problems. It’s important to take the medication exactly as prescribed and complete the full course, even if symptoms improve earlier. Skipping doses or stopping early can lead to treatment failure or antibiotic resistance.
